Schenk, Philipp https://orcid.org/0000-0001-6044-1068
Devine, Shane M https://orcid.org/0000-0001-8727-7392
Cobbold, Simon A https://orcid.org/0000-0002-9927-8998
Geoghegan, Niall D
Kyran, Elizabeth L
Ang, Ching-Seng
Alexandrovics, Jack A
Calleja, Dale J https://orcid.org/0000-0002-8306-0900
Multari, Dylan H https://orcid.org/0000-0001-6932-9881
Vaibhav, Vineet
Lu, Bernadine G C https://orcid.org/0000-0001-8044-9710
Klemm, Theresa A https://orcid.org/0000-0002-2847-3550
Dagley, Laura F
Lowes, Kym N
Williamson, Nicholas A https://orcid.org/0000-0002-2173-3452
Eichhorn, Pieter J A https://orcid.org/0000-0001-5840-943X
Ng, Ashley P https://orcid.org/0000-0001-9690-0879
Feltham, Rebecca https://orcid.org/0000-0001-8376-6869
Komander, David https://orcid.org/0000-0002-8092-4320
Funding for this research was provided by:
DHAC | National Health and Medical Research Council (GNT117812)
University of Melbourne
Leukemia Foundation Breakthrough Fellowship
DHAC | Medical Research Future Fund (EPCD000033)
Victorian Government
CCA | Cancer Council Western Australia (CCWA2025/1401)
The Galbraith Family Charitable Trust
K & M Foundation for Women
Betty Deller King Bequest
Denise and Roberto Cappai
John and Tibby Peterson
Rae Foundation
Berwick opportunity shop
Article History
Received: 9 June 2025
Revised: 9 February 2026
Accepted: 20 February 2026
First Online: 7 April 2026
Disclosure and competing interests statement
: DK is the founder, shareholder and SAB member of Entact Bio and Proxima Bio, and co-founder and SAB member of Ternarx. RF is co-founder and scientific lead at Ternarx. APN is co-founder and clinical advisor at Ternarx.